![emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education](https://i0.wp.com/www.emdocs.net/wp-content/uploads/2019/04/Screen-Shot-2019-04-21-at-5.23.21-PM.png?fit=1576%2C1064&ssl=1)
emDOCs.net – Emergency Medicine EducationPush-Dose Vasopressors: An Update for 2019 - emDOCs.net - Emergency Medicine Education
![Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-021-01632-2/MediaObjects/41416_2021_1632_Fig2_HTML.png)
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer
![First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine](https://www.thelancet.com/cms/asset/2e367137-80c0-40c6-9ddd-bcd689ba8a67/gr1.jpg)
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine
![Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals](https://pub.mdpi-res.com/vaccines/vaccines-11-00781/article_deploy/html/images/vaccines-11-00781-g001.png?1680494606)
Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals
![Definition of the dose change intervals and construction of features.... | Download Scientific Diagram Definition of the dose change intervals and construction of features.... | Download Scientific Diagram](https://www.researchgate.net/publication/328430592/figure/fig3/AS:959288084295682@1605723510459/Definition-of-the-dose-change-intervals-and-construction-of-features-The-top-panel-a.png)
Definition of the dose change intervals and construction of features.... | Download Scientific Diagram
![Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation](https://www.frontiersin.org/files/MyHome%20Article%20Library/1086258/1086258_Thumb_400.jpg)
Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation
![Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2021/edbk.2021.41/edbk_319783/20210531/images/large/edbk_319783-table1.jpeg)
Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book
![Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419322458-gr1.jpg)
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect
![Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram](https://www.researchgate.net/publication/350835604/figure/fig1/AS:1012002675761152@1618291648006/Study-design-a-Framework-for-the-dose-escalation-and-dose-expansion-study-of.png)
Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram
Bavdegalutamide (ARV-110): Phase 1 Dose Escalation and Interim ARDENT Phase 2 Dose Expansion Trial Results
![Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram](https://www.researchgate.net/publication/46403694/figure/fig2/AS:667189245931545@1536081720859/Inter-patient-and-intra-patient-dose-escalation-strategy-Patients-were-sequentially.png)
Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram
![Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S095980492100040X-gr1.jpg)
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - ScienceDirect
![Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01632-2/MediaObjects/41416_2021_1632_Fig1_HTML.png)